the the business. am targeting afternoon, or disease you vascular update today devices developing us. Thanks, our dermatology I'll Good Pharos of artery large and we transaction pleased market PAD. and joining on a competitive Jody. thank progress product to sale medical peripheral everyone, portfolio the announced to this with for you discuss have treat growing to for I opportunity and our and to begin
with this explore of with options evaluating advisor. been decision Medical conference assistance multiple As business discussed shareholders the the of during have call, the sale of extensive the a business the Pharos we strategic goal the with of Ra to last building value financial for a quarter’s evaluation for result
we believe interest we the intend as the sold provides PAD We this related and the of third-party immediate at million to focused further more which a XX pleased company million very U.S. transaction CTO vascular An for transaction to us to the to Skin are The million Pharos PAD $XXX with allows we and market business atherectomy research the our result, market. maximize devices to a assets reduce in our than in have proceeds STRATA is to transaction the future. best burn As in in specifically XXXX. cash in XX the cash people estimated shareholders strategy value a and and initiatives on to Sciences. places have closed U.S. our
space year, this a products pure-play putting focused challenges companies managing perspective, ever-evolving the company is with and sincerely are in confident dermatology we to I the the the COVID-XX that tackling good Pharos patient the peer the want margins skin in valuation line In on and the also multiples. pandemic. addition, STRATA with market have therapeutic a past thank hands. the commitment From business posed to during team robust enjoy very a product I gross individuals conditions. for many their high relatively performance chronic am by sustained Pharos
in to a decision performance. no Our sell of their this way reflection business was
because several transaction path buy forward. our In fact, interest that of their of relative we to it's to this the points business. expressions would make I performance like and had to
to study DABRA milestones focus on strategic resources generation the we of our will we completion vascular next of clinical our indication. majority with achievement and obtain catheter FDA associated an continue the products and First, of the our the value a allocate to on have atherectomy business clear creating
of shock potential growth vessels in to technology waves intravascular Second, represents minute. fracture a in this can lithotripsy. we as a calcified This and of exciting markets. I PAD artery talk an calcium, our explore application more to opportunity coronary arterial to referred our application technology sometimes to treat have begun will about the disease that DABRA possible create application
provide a our clarity and to runway. provides burn of evaluating mentioned as investors our while terms divestiture our fund our potential immediate in company. fourth, cash should vascular extending Third, cash becoming initiatives this earlier, future to company and valuing vascular reducing also more And cash our pure-play
obtain now start business. FDA Turning study indication. DABRA clinical an atherectomy to our our to I'll with
to the study is locations As currently a XX is Call Investor subjects. moved the the to early unpredictable we and Four subjects study, XX up enrollment continued sites being continued and to sites trial, an XX will May, clinical on of fifth enrolled subjects appreciate enroll the the pandemic previously Yet estimate XXX to of with work challenges team subjects. be enrollment to unable due our total summer vacations which impact are enrollment site, given cleared precision still cleared, the bringing the additional date process a pace and completed. for last clinical we in COVID-XX. has to pleased in be are navigate to our and with of Since reminder, to was approved reactivated. of and I when in this have
a catheter an the us and like would submission the being study. for on DABRA clearance in changes shelf initiatives The life. made to I currently data for various next additional an their The provide to of DABRA used catheters. system our Next, submission update support and two-month we've the included engineering recent clinical DABRA incorporated generation to completed XXX(k) atherectomy granted our review FDA
clearance evaluating commercial potential plans very from of are agency. for catheter still this receive limited the release pleased and a are this We to
months aging the we accelerated addition, data for In for mitigation generated aging support life believe the we develop configurations finalize requisite data and efforts, of have shelf In support a real-time this a various and have future plan for to sterilization future Later to catheter least short, that life catheters. year, changes including XX material outcomes. achievement catheters. process will produced a generation our shelf the we at six-month desired needed of
We the next to catheter generation QX. design freeze development make on catheter projects. also team DABRA achieved our milestone progress Our continues in our good for
deliverable anatomy. overjacket it and this catheter you As when tortuous a make braided incorporates will recall, gen to kink-resistant navigating next more
hands-on with While and robustness team XXXX. this catheter. physicians design This is added for are another first in the some increase previous I looking a manufacturing engineering design feedback with guidewire first the will the all against The with process-related quarter to prototypes generation now The guidewires. during supplier FDA DABRA was peripheral Ra previously clear of performance physicians catheter with overall workshop tracking XXX extremely physician expectation work further. expect catheter of experienced we challenges work verification the our the and performing our of year. In In in am we quarter DABRA we workshop will to the of later progress, compatible than resolved. were schedule standard interventional complete end catheter our exactly for completed regulatory to rather We and design builds, is interventions. is our intend proceeding with feedback, evaluated engineering catheter DABRA fourth we the design goal. clearance new what summary, in of these June on will few valuable by that changes response various encountered compatible I gen XXXX file we be even making over for. With of guidewire the XXXX. well is a improvement work overall design our the the this be confident an compatibility conduct received the during with leverages interventional Medical next improved that the project described this team catheter We have
initiatives. additional R&D, leaving Before two address want I to
to end a design we laser for continue year. upgrades and on the work to CPU completing execute the by various of new this First, system with front development anticipate DABRA the
the who the to promising external past experts Second, we conjunction early are months over have conducted company. in research with some several
referred thus the to system be waves subsequent Our to to of commonly create work calcium or sufficient peripheral can arteries is can to making of and/or procedure procedures in type as easier calcium that help coronary safer and This has arteries. intravascular magnitude fracture shock arteries rigid less demonstrated perform. DABRA Fracturing the make utilized lithotripsy. laser
confirm prototypes fabricate to initial our preclinical conduct to results. is step next systems a benchtop study and several Our
Although to our I and the I potential activities will early, quite it's value. unmet still of during system future calls. create additional potential significant need the this updates huge clinical about excited shareholder given am DABRA on provide application very the
of to continuing of engineering company hard during patients, their a and in enrolling I'd of Medical team the critical Ra world clinical for achieve focusing done at Lastly, thank Everyone and job an to the entire needs the at continued amazing a change and us. our customers uncertainty the milestones. significant and work around on study like period has their dedication
call financial provide Pharos Andrew? turn the discuss Now, over I to about our the additional Andrew details transaction. will to results and
